Ulcerative colitis treatment : an insight into daily clinical practice

Abstract

Background : The natural history of ulcerative colitis (UC) is unpredictable. Factors associated with the need for different types of step-up therapy in UC patients failing on 5-aminosalicylic acid (5-ASA) or corticosteroids are understudied. Aims : Describe step-up therapy in patients with UC the first year after failing on 5-ASA or corticosteroids. Methods : A Belgian, multi-center, prospective, non-interventional observational study comprising adult UC patients failing on 5-ASA or corticosteroids and naive to immunomodulators/biologicals. During a 12 months follow-up, patient characteristics, demography, medical therapy, biomarkers, therapy adherence and quality of life (QoL) were assessed. Results : After 1 year, 35% of the patients were on biological therapy. Use of anti-TNF; differed depending on baseline treatment: corticosteroid-refractory patients (55.8%), 5-ASA refractory (20.0%), and corticosteroid-dependent (16.0%) patients (p<0.001). The decision to start a line of therapy was based on the Mayo combined severity but not on biomarkers like faecal calprotectin, haemoglobin, CRP, albumin, platelets, and number of extra-intestinal manifestations. At year 1, 84.2% of the patients had only mild CC or remission and a significant improvement of fatigue (p=0.004) and IBDQ scores (p<0.001) were observed implying an improved QoL. Conclusion : Treatment step-up, based on clinical scores in immunomodulatory and anti-TNF naive patients with UC, provides good clinical outcomes and QoL.